Merck (MRK) Cash & Equivalents (2009 - 2026)

Merck (MRK) has reported Cash & Equivalents for 18 consecutive years, with $6.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 14.46% year-over-year to $6.8 billion in Q2 2026; TTM through Jun 2026 was $6.8 billion, a 14.46% decrease from a year earlier, with the FY2025 full-year figure at $14.6 billion, up 9.99% from the prior year.
• Cash & Equivalents was $6.8 billion for Q2 2026 at Merck, up from $5.3 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $18.2 billion in Q3 2025 and troughed at $5.3 billion in Q1 2026.
• A 5-year average of $10.0 billion and a median of $9.2 billion in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 46.11% in 2023 and surged 99.72% in 2024, its largest moves.
• Over 5 years, Cash & Equivalents stood at $12.7 billion in 2022, then slumped by 46.11% to $6.8 billion in 2023, then jumped by 93.57% to $13.2 billion in 2024, then climbed by 9.99% to $14.6 billion in 2025, then tumbled by 52.98% to $6.8 billion in 2026.
• The last three Cash & Equivalents figures came in at $6.8 billion (Q2 2026), $5.3 billion (Q1 2026), and $14.6 billion (Q4 2025), per Business Quant data.